The European Commission has reportedly halted its merger investigation into Zimmer Holding’s proposed acquisition of Biomet, announcing Thursday that the regulator will need more information on the deal.
US-based orthopedic product maker Zimmer is looking to acquire Biomet for $13.4 billion, but according to the EU regulator, the merger filing lacks crucial information for the Commission to properly asses the deal. The submission for the deal was filed June 3.
Reports say the transaction would create the industry’s second-largest player behind Johnson & Johnson.
The Commission announced Thursday that the merger application was “incomplete,” causing the watchdog to scrap its initial July 9 date for merger review completion. A new date will be set following the acquisition of the requested information.
Full content: Interactive Investor
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
BHP Unveils £31bn Mining Megamerger Proposal with Anglo American
Apr 25, 2024 by
nhoch@pymnts.com
ByteDance Prefers Shutdown Over Sale of TikTok Amid US Ban Threats
Apr 25, 2024 by
CPI
FCC Votes to Restore Net Neutrality Rules
Apr 25, 2024 by
nhoch@pymnts.com
Apple Rejects Spotify’s Updated App Over In-App Pricing Disclosure
Apr 25, 2024 by
CPI
FCC Set to Reinstate Net Neutrality Rules Today
Apr 25, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Economics of Criminal Antitrust
Apr 19, 2024 by
CPI
Navigating Economic Expert Work in Criminal Antitrust Litigation
Apr 19, 2024 by
CPI
The Increased Importance of Economics in Cartel Cases
Apr 19, 2024 by
CPI
A Law and Economics Analysis of the Antitrust Treatment of Physician Collective Price Agreements
Apr 19, 2024 by
CPI
Information Exchange In Criminal Antitrust Cases: How Economic Testimony Can Tip The Scales
Apr 19, 2024 by
CPI